2009-11-10 12:38:04 - Daniel Junius, President and Chief Executive Officer. “We’ll be reporting updated clinical data with our IMGN901 compound when used for the treatment of CD56-expressing solid tumors.
Full Article at PR-Inside.com
Related Quotes
There are no results for this module. Edi the module to change the search term used to query related quotes.
We built Daylife.com using our SmartMedia Services platform, which can give you thousands of content-rich, advertiser-friendly pages (like this one) on any topic and with full editorial control. Learn More »